Assessing a Rare and Serious Adverse Event Following Administration of the Ad26.COV2.S Vaccine

doi:10.1001/jama.2021.7637

Editorial

. 2021 Jun 22;325(24):2445-2447.

doi: 10.1001/jama.2021.7637.

Assessing a Rare and Serious Adverse Event Following Administration of the Ad26.COV2.S Vaccine

Ruth A Karron¹, Nigel S Key², Joshua M Sharfstein³

Affiliations

¹ Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland.
² Department of Medicine, University of North Carolina at Chapel Hill.
³ Department of Health Policy and Management, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland.

PMID: 33929484
DOI: 10.1001/jama.2021.7637

Editorial

Assessing a Rare and Serious Adverse Event Following Administration of the Ad26.COV2.S Vaccine

Ruth A Karron et al. JAMA. 2021.

. 2021 Jun 22;325(24):2445-2447.

doi: 10.1001/jama.2021.7637.

Authors

Ruth A Karron¹, Nigel S Key², Joshua M Sharfstein³

Affiliations

¹ Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland.
² Department of Medicine, University of North Carolina at Chapel Hill.
³ Department of Health Policy and Management, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland.

PMID: 33929484
DOI: 10.1001/jama.2021.7637

No abstract available

PubMed Disclaimer

Comment on

US Case Reports of Cerebral Venous Sinus Thrombosis With Thrombocytopenia After Ad26.COV2.S Vaccination, March 2 to April 21, 2021.
See I, Su JR, Lale A, Woo EJ, Guh AY, Shimabukuro TT, Streiff MB, Rao AK, Wheeler AP, Beavers SF, Durbin AP, Edwards K, Miller E, Harrington TA, Mba-Jonas A, Nair N, Nguyen DT, Talaat KR, Urrutia VC, Walker SC, Creech CB, Clark TA, DeStefano F, Broder KR. See I, et al. JAMA. 2021 Jun 22;325(24):2448-2456. doi: 10.1001/jama.2021.7517. JAMA. 2021. PMID: 33929487 Free PMC article.

Cited by

Immunity and Protective Efficacy of a Plant-Based Tobacco Mosaic Virus-like Nanoparticle Vaccine against Influenza a Virus in Mice.
Madapong A, Petro-Turnquist EM, Webby RJ, McCormick AA, Weaver EA. Madapong A, et al. Vaccines (Basel). 2024 Sep 26;12(10):1100. doi: 10.3390/vaccines12101100. Vaccines (Basel). 2024. PMID: 39460267 Free PMC article.
Response of Unvaccinated US Adults to Official Information About the Pause in Use of the Johnson & Johnson-Janssen COVID-19 Vaccine: Cross-Sectional Survey Study.
Mishra V, Dexter JP. Mishra V, et al. J Med Internet Res. 2024 Apr 1;26:e41559. doi: 10.2196/41559. J Med Internet Res. 2024. PMID: 38557597 Free PMC article.
Relationship Between Coronavirus Disease 2019 Vaccination Rates and Rare But Potentially Fatal Adverse Events: A Regression Discontinuity Analysis of Western Countries.
Chae SH, Park HJ, Radnaabaatar M, Park H, Jung J. Chae SH, et al. J Korean Med Sci. 2023 Mar 20;38(11):e94. doi: 10.3346/jkms.2023.38.e94. J Korean Med Sci. 2023. PMID: 36942397 Free PMC article.
COVID-19 Vaccine-Induced Immune Thrombotic Thrombocytopenia (VITT) and Cerebral Venous Sinus Thrombosis (CVST)- Lessons for India.
Khan E, Bavishi S, Sharma AK, Sharma VK, Goyal V. Khan E, et al. Ann Indian Acad Neurol. 2022 Jan-Feb;25(1):15-20. doi: 10.4103/aian.aian_669_21. Epub 2021 Oct 22. Ann Indian Acad Neurol. 2022. PMID: 35342247 Free PMC article.
COVID-19 Vaccine-Induced Pro-thrombotic Immune Thrombocytopenia (VIPIT): State of the Art.
Calcaterra G, Bassareo PP, De Gregorio C, Barilla F, Romeo F, Mehta JL. Calcaterra G, et al. Curr Cardiol Rev. 2022;18(5):11-17. doi: 10.2174/1573403X18666220321105909. Curr Cardiol Rev. 2022. PMID: 35319381 Free PMC article.

See all "Cited by" articles

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions

LinkOut - more resources

Full Text Sources
- Ovid Technologies, Inc.
- Silverchair Information Systems
Medical
- MedlinePlus Health Information

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Assessing a Rare and Serious Adverse Event Following Administration of the Ad26.COV2.S Vaccine

Affiliations

Assessing a Rare and Serious Adverse Event Following Administration of the Ad26.COV2.S Vaccine

Authors

Affiliations

Comment on

Similar articles

Cited by

Publication types

MeSH terms

Substances

LinkOut - more resources

Full Text Sources

Medical